Gyre Therapeutics, Inc. GYRE Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s investing cash flow?
- Gyre Therapeutics, Inc. (GYRE) reported investing cash flow of -$3.06M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Gyre Therapeutics, Inc.'s investing cash flow decreased by 255.3% year-over-year, from $1.97M to -$3.06M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s investing cash flow?
- Over 3 years (2021 to 2024), Gyre Therapeutics, Inc.'s investing cash flow has grown at a -25.6% compound annual growth rate (CAGR), from $48.19M to -$19.88M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.